Linezolid Sandoz (Linezolid)

Linezolid is an oxazolidinone antibiotic used to treat serious Gram‑positive bacterial infections.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective for skin, bloodstream and lung infections caused by MRSA.
• Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative treatment option for VRE bloodstream and urinary tract infections.
• Community‑acquired bacterial pneumonia: used to treat pneumonia caused by susceptible Streptococcus pneumoniae and other pathogens.
• Skin and soft tissue infections: indicated for complicated infections caused by susceptible Gram‑positive organisms.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This action blocks the early stage of peptide chain assembly, leading to a bacteriostatic effect against susceptible Gram‑positive organisms, including MRSA and VRE. The binding site is distinct from that of other protein synthesis inhibitors, which reduces cross‑resistance, and the drug penetrates well into lung tissue and skin.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste perception.
• Rash: mild skin erythema.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Myelosuppression: anemia, thrombocytopenia or neutropenia.
• Peripheral neuropathy: sensory disturbances with prolonged use.
• Lactic acidosis: rare metabolic disturbance.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing Linezolid, clinicians should consider several safety and handling precautions.

• Monitor blood counts: regular CBC testing to detect myelosuppression.
• Assess liver function: check hepatic enzymes before and during therapy.
• Evaluate renal function: dose adjustment may be needed in severe impairment.
• Avoid concomitant serotonergic drugs: risk of serotonin syndrome.
• Counsel on potential taste changes: patients may experience metallic taste.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Linezolid interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid)

• SSRIs and other serotonergic agents: risk of serotonin syndrome.
• MAO inhibitors: may cause hypertensive reactions.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase anticoagulant effect, monitor INR.
• Carbamazepine and other enzyme‑inducing anticonvulsants: may lower linezolid levels.
• Oral contraceptives: possible reduction in efficacy, consider backup method.